Replimune stock.

Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...Replimune Group Stock Performance Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of …Replimune Group Inc (REPL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News DIA 0.02% 5.71% GST.X 26.01% SKL.X 34.16% KAS.X 1.70% KDA.X …

8 Des 2022 ... ... Replimune's asset could be the go-to product when anti-PD-1 therapy has failed. The stock closed up 22% yesterday, allowing the group to ...

10.39 +0.10 (0.97%) At close: Nov 24, 2023, 1:00 PM 10.86 +0.46 (4.48%) After-hours: Nov 24, 2023, 1:26 PM EST Financials No 1Y chart data available About …Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High

Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority. Replimune Announces Pricing of Public Offering | Replimune BOSTON , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of …Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc. On September 12, 2023, Pamela Esposito, the Chief Business Officer of Replimune Group Inc (NASDAQ:REPL), sold 5,658 shares ...REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.

Our Science. Cancer involves a failure of the immune system in one of two ways: 1) the immune system is unable to recognize the tumor as foreign, and/or 2) the immune response is disabled or shut down by the tumor. Replimune is pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter ...

Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...

Replimune Group Stock Price | REPL Stock Quote, News, and History | Markets Insider The latest Replimune Group stock prices, stock quotes, news, and …Aug 14, 2023 · Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock. 2 days ago · What is the target price for Replimune Group (REPL) stock? A The latest price target for Replimune Group ( NASDAQ : REPL ) was reported by HC Wainwright & Co. on Monday, November 13, 2023 . Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ... REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POST

Replimune Group Inc. Watch list Set a price target alert After Hours Last Updated: Nov 29, 2023 4:02 p.m. EST Delayed quote $ 11.32 0.00 0.00% After Hours Volume: 16.73K Advanced Charting Volume:...Indeed, Replimune Group (NASDAQ:REPL) stock is up 152% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all ...Replimune will never request any financial information, funds, or passport details as part of the recruitment process. We employ a formal process that includes an interview with a member of our HR team. This is required and the only way to secure an employment offer from Replimune.They pay benefits on behalf of the employees. Healthcare and life insurance without premiums. Good benefits, could use HSA. Great benefits, growing company, plenty to learn. Free health care is very good. Good stock options, and retirement matching.Novartis AG. -0.52%. CHF176.38B. REPL | Complete Replimune Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.

Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...19 Sep 2023 ... The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock ...

A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Get Replimune Group Inc (REPL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsChristopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …Replimune Group Enters Oversold Territory (REPL) Dividend Channel - Fri Feb 11, 4:10PM CST . Legendary investor Warren Buffett advises to be fearful when others are greedy, …Stock Price. $14.2. 2023-11-03. Market Capitalization. $837.7 M. 2023-11-03. Replimune Summary. Company Summary. Overview. Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens ...Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients. About Us.

Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The REPL shares have gain 12.70% over the last week, with a monthly amount drifted -18.05%, and not seem to be holding up well over

REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POSTREPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54. Why Replimune Stock Is Soaring Today. 485%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 485% . S&P 500 Returns. 126%.Replimune Group, Inc. Common stock $ per share . Replimune Group, Inc. is offering 5,000,000 shares of common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol "REPL." On November 11, 2019, the last reported sale price of our common stock on Nasdaq was $17.21 per share. ...PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority. Dec 4, 2023 · Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08. Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in ...Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days. Replimune Group : The very small 0.44% REPL stake saw a ~18% increase last quarter at prices between ~$17 and ~$28. The stock is now at ~$19. The stock is now at ~$19. Note: they have a ~10% ...

Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis.Replimune Group Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more.A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. See Replimune Group, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Based on 10 analysts giving stock ratings to REPL in the past 3 months. EPS. …Instagram:https://instagram. elderly care at home costsholiday stock market hourspstg stock pricebuying tips 2 days ago · What is the target price for Replimune Group (REPL) stock? A The latest price target for Replimune Group ( NASDAQ : REPL ) was reported by HC Wainwright & Co. on Monday, November 13, 2023 . Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days. tqqq dividend history1979 liberty silver dollar Jul 9, 2023 · Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy. kennedy dollar coin value Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively ...BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …